单位：[1]Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, P. R. China首都医科大学附属天坛医院[2]Beijing Engineering Research Center of Immunological Reagents Clinical Research, Beijing 100070, P. R. China[3]Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, P. R. China首都医科大学附属天坛医院[4]Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, P. R. China医技科室药学部首都医科大学附属北京友谊医院
Background: Certain patients experience muscle-related adverse effects after taking atorvastatin. Genetic factors play an important role in the occurrence of statin-induced myopathy. Aim: We aimed to identify genetic variants associated with statin-induced myotoxicity. Methods: We prospectively enrolled 1,102 acute ischemic stroke patients who underwent atorvastatin treatment for the first time after admission. Patients were separated into case and control groups after a follow-up of 3 months. We used a biochemical definition of myopathy consisting of serum creatine kinase values more than ten times the upper limit of normal for the reference laboratory (150 U/L). Fifty single nucleotide polymorphisms SNPs) from seven genes of ABCB1, CoQ2, HTR3B, RYR2, CYP3A5, HTR7 and SLCO1B1 were selected and genotyped. The effects of genetic polymorphisms on myopathy were observed. Results: 61 cases and 110 controls were recruited in the study. Compared with the controls, the cases had a significant higher mutant frequency of the allele A (ABCB1, rs2373588) (OR= 2.01, 95%CI = 1.10-3.67, P = 0.001) and a significant lower mutant frequency of the allele A (SLCO1B1, rs976754) (OR = 1.85, 95%CI = 1.12-3.03, P = 0.042). Genotypes or alleles of the other SNPs had no significant difference between the two groups (P > 0.05). Conclusion: Our findings reveal that SLCO1B1 and ABCB1 genetic variants are associated with statin-induced myopathy. These are valuable biomarkers for the evaluation of atorvastatin safety.
基金：
Beijing Municipal Natural Science FoundationBeijing Natural Science Foundation [7192060]; Beijing Municipal Administration of Hospitals' Youth Programme [QML20170506]; Youth Science Fund of Beijing Tiantan Hospital [2016-YQN-09]; Research incubation fund of Capital Medical University [PYZ2017067]
第一作者单位：[1]Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, P. R. China[2]Beijing Engineering Research Center of Immunological Reagents Clinical Research, Beijing 100070, P. R. China
通讯作者：
通讯机构：[1]Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, P. R. China[2]Beijing Engineering Research Center of Immunological Reagents Clinical Research, Beijing 100070, P. R. China[4]Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, P. R. China[*1]Laboratory Diagnosis Center, Beijing Tiantan Hospital, Capital Medical University, west road of south fourth ring, the 119th, Fengtai District, Beijing 100070, P. R. China[*2]Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Road 95 Yongan, Xicheng District, Beijing 100050, P.R. China
推荐引用方式(GB/T 7714)：
Zhang Limin,Lv Hong,Zhang Qian,et al.Association of SLCO1B1 and ABCB1 Genetic Variants with Atorvastatin-induced Myopathy in Patients with Acute Ischemic Stroke[J].CURRENT PHARMACEUTICAL DESIGN.2019,25(14):1663-1670.doi:10.2174/1381612825666190705204614.
APA：
Zhang, Limin,Lv, Hong,Zhang, Qian,Wang, Dongzhi,Kang, Xixiong...&Li, Xingang.(2019).Association of SLCO1B1 and ABCB1 Genetic Variants with Atorvastatin-induced Myopathy in Patients with Acute Ischemic Stroke.CURRENT PHARMACEUTICAL DESIGN,25,(14)
MLA：
Zhang, Limin,et al."Association of SLCO1B1 and ABCB1 Genetic Variants with Atorvastatin-induced Myopathy in Patients with Acute Ischemic Stroke".CURRENT PHARMACEUTICAL DESIGN 25..14(2019):1663-1670
：